TBPH
What is Theravance Biopharma's (TBPH) economic moat?
Theravance Biopharma (TBPH)'s economic moat is graded on the Buffett-Fit framework using two quantitative anchors and qualitative signals. The current ROIC sits at -0.0% (0.2% over 5y average) and the gross margin runs at 1.0%. Whether that constitutes a durable competitive advantage depends on whether those returns can be sustained, covered below. Educational only, not investment advice.
ROIC sustainability. Theravance Biopharma's trailing ROIC is -0.0%, with a 5-year average of 0.2%. ROIC above 15% sustained over multiple years is the closest single quantitative proxy for moat strength: it means capital deployed in the business is earning above-average returns AND competitors haven't been able to compete those returns away. A one-year spike from a hot product cycle doesn't count; the pattern needs to hold across a full business cycle.
Gross-margin durability. Theravance Biopharma runs a gross margin of 1.0%. Sustained gross margins above 40% in industries where peers sit lower is direct evidence of pricing power, customers are willing to pay a premium without switching, which is what a moat actually feels like in the income statement. Margin compression over multiple years signals the moat is eroding.
Qualitative signals. Beyond the numbers, moat sources include brand strength (consumer staples, luxury), switching costs (enterprise software, banking), network effects (marketplaces, payment networks), regulatory barriers (utilities, insurance), and patents (pharma, semiconductors). The Buffett-Fit verdict on /buffett/tbph/ identifies which of these apply to Theravance Biopharma specifically. The moat pillar contributes roughly 25% of the overall Buffett-Fit score.
How invest-like measures this
An economic moat is a structural advantage that lets a business earn above-average returns on capital over long stretches without those returns being competed away. The Buffett-Fit moat pillar grades it via two quantitative anchors (ROIC sustainability, gross-margin durability) plus qualitative signals like brand strength, switching costs, network effects, regulatory barriers, and patent moats.
ROIC above 15% sustained over a multi-year window (not a single hot year) is the closest single quantitative proxy for moat strength. Sustained gross margins above 40% in industries where peers sit lower is real pricing power. Both are necessary, neither is sufficient on its own.
This is educational analysis based on investing frameworks. It is not investment advice or a recommendation, and it does not know your situation. Do your own research before you decide.
